Any current/future new fundraising through debt or equity?

Promoters have been increasing their shareholding year on year through warrant conversions, with 6 lakh warrants issued and converted in the current year, adding funds to the company. There is a restriction of increasing promoter shareholding by no more than 5% annually. No explicit mention of plans for new fundraising through debt or fresh equity outside promoter warrants conversion. Capex planned for FY '27 is relatively low at INR 4 to 4.5 crores, indicating no major immediate need for large-scale fundraising. The company focuses on organic growth and ramp-up of existing facilities rather t

Any current/future capex/capital investment/strategic investment?

Major capex cycle is currently over; all plants are operational. FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun. No significant new capex expected in FY '27 beyond this recurring amount. Future growth is expected from ramp-up and approvals rather than large new investments. The Pune infusion JV plant is operational and ramping up capacity gradually; no major capex mentioned specifically for this. Regulatory approvals and product portfolio expansion drive growth rather than fresh capital expenditure

Future growth expectations in sales/revenue/volumes?

FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27. Base business expected to grow around 18-20% in FY '27-'28, potentially higher. Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa. Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27. Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14. Export markets to cont

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26). SPL Infusion (JV Pune plant) expected to contribute INR 60-65 crores in FY '27. EBITDA margins for base business expected to remain at 16-17%; Pune JV plant targeting 17-18% initially, with potential to improve with higher utilization. Base business growth anticipated at around 18-20% in FY '27 and FY '28. Pune infusion plant ramp-up expected from 20-25% utilization presently to 40-50% by next year. Margins improved due to better product mix and expected to sustain. Promoters plan annual incrementa

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders. However, it indicates strong growth driven primarily by export markets and product mix improvements. The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow. The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December. Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28. Overall, business growth and increase in capa

IN US

Sale is live|00:00:00left today

Sanjivani Paranteral LtdQ4 FY27Pharmaceuticals & Biotechnology

Sanjivani Paranteral Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹147P/E: 24.0Market Cap: ₹197 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
→SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
→Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
→Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
→Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
→Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
→Export markets to continue being key revenue drivers, contributing ~77% of total revenue.
→Expectation of 15-25% growth in base exports business starting Q2/Q3 FY '27 due to capacity utilization and approvals.
→Recurring capex of INR 4-4.5 crores annually for maintenance and upgrades; no major new capex planned.

Margin guidance

Category 3

→FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).
→SPL Infusion (JV Pune plant) expected to contribute INR 60-65 crores in FY '27.
→EBITDA margins for base business expected to remain at 16-17%; Pune JV plant targeting 17-18% initially, with potential to improve with higher utilization.
→Base business growth anticipated at around 18-20% in FY '27 and FY '28.
→Pune infusion plant ramp-up expected from 20-25% utilization presently to 40-50% by next year.
→Margins improved due to better product mix and expected to sustain.
→Promoters plan annual incremental shareholding, potentially supporting stronger financial backing.
→Capex for FY '27 is about INR 4-4.5 crores, mainly for maintenance and upgrades, indicating no major expansion capex in near term.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Promoters have been increasing their shareholding year on year through warrant conversions, with 6 lakh warrants issued and converted in the current year, adding funds to the company.
→There is a restriction of increasing promoter shareholding by no more than 5% annually.
→No explicit mention of plans for new fundraising through debt or fresh equity outside promoter warrants conversion.
→Capex planned for FY '27 is relatively low at INR 4 to 4.5 crores, indicating no major immediate need for large-scale fundraising.
→The company focuses on organic growth and ramp-up of existing facilities rather than new capital raising at this stage.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders.
→However, it indicates strong growth driven primarily by export markets and product mix improvements.
→The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
→The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
→Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28.
→Overall, business growth and increase in capacity utilization imply a healthy and growing order pipeline, though specific orderbook numbers are not disclosed.

Capex plans

Yes

→Major capex cycle is currently over; all plants are operational.
→FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
→No significant new capex expected in FY '27 beyond this recurring amount.
→Future growth is expected from ramp-up and approvals rather than large new investments.
→The Pune infusion JV plant is operational and ramping up capacity gradually; no major capex mentioned specifically for this.
→Regulatory approvals and product portfolio expansion drive growth rather than fresh capital expenditure.
→Strategic investments include a JV in IV fluids and a nutraceutical venture in Europe, currently at ramp-up and commercialization phases.

How does Sanjivani Paranteral Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sanjivani Paranteral Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sanjivani Paranteral Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio